Exscientia

We’re excited that Nicola Richmond Ph.D., will be joining the Exscientia team in September as Chief Scientist, AI. With a Ph.D. in mathematics, she brings over 20 years of experience operating at the intersection of drug discovery and technology. Nicola will be leading Exscientia’s work to develop AI solutions for the Company’s drug discovery efforts.  #AI #DrugDiscovery

We’re looking forward to welcoming attendees to the Quantum Mechanics in Pharma 1-day meeting, taking place in London on 18 September at SOAS University of London. We’re organising this event in collaboration with the Molecular Graphics and Modelling Society. The meeting aims to highlight some of the key developments of quantum mechanics applied in the pharmaceutical industry, and stimulate discussion about the future direction of new and emerging methodologies. To find out more and to buy tickets please visit https://lnkd.in/e4rvRgCM #drugdiscovery #compchem #QM #machinelearning

Watch Chris Gibson, Co-Founder and CEO of Recursion, and Dave Hallett, Interim CEO of Exscientia, talk more about the plan to bring together the people, partnerships, pipelines and research platforms of Exscientia and Recursion to truly accelerate the discovery of better drugs for patients. #techbio #ai #drugdiscovery #pharma

Watch Chris Gibson, Co-Founder and CEO of Recursion, and Dave Hallett, Interim CEO of Exscientia, talk more about the plan to bring together the people, partnerships, pipelines and research platforms of Exscientia and Recursion to truly accelerate the discovery of better drugs for patients. #techbio #ai #drugdiscovery #pharma

We’re excited to announce today that we’ve entered into a definitive agreement with Recursion (Nasdaq: RXRX). This proposed combination of Exscientia’s Generative AI drug design and chemistry automation capabilities and Recursion’s high throughput target biology will help us deliver better treatments to patients faster and at a lower cost. We believe the proposed combination creates numerous synergies and benefits across: Platform: The proposed combination enables the assembly of a platform that leverages technology to enable a full-stack discovery solution spanning patient-centric target discovery, hit discovery, lead optimisation, automated chemical synthesis, predictive ADMET and translation, biomarker selection, clinical development, and more. Pipeline: We believe the combination with Recursion will result in a diverse portfolio of clinical or near-clinical programs with approximately 10 clinical readouts expected in the next 18 months where most of these programs, if successful, could have peak sales opportunities in excess of $1 billion. Partnerships: The proposed business combination will also advance transformative therapeutic discovery collaborations with some of the most prominent biopharma companies in the world, including Roche-Genentech, Sanofi, Bayer, and Merck KGaA, along with the potential for additional milestone payments of approximately $200 million over the next two years from current partnerships. We’re excited that we will be bringing these two great teams together and look forward to being able to accelerate our ability to deliver first-in-class and best-in-class treatments to patients who need them most. https://lnkd.in/eYfUXFgP #techbio #pharma #partnership #agreement #pipeline #ai #drugdiscovery

Xcellomics calling for new screening proposals Xcellomics is a collaboration between the academic community, the University of Oxford and Exscientia.   We’re seeking novel, in vitro or ex vivo, pathologically relevant cellular assays that have the potential to be developed into small molecule or functional genomic CRISPR screens. If you’d like to apply and help identify novel drug targets in cancers with high unmet need please visit: https://lnkd.in/g9gPgGsS    Closing date for submissions is 15 September 2024.

ICYMI: Hear from Dave H. and Tanuja Randery on the digital transformation of drug R&D and the role of AI, including Dave’s views of the future of using technology to speed up the design and discovery of novel drug candidates and his vision for Exscientia. #AI #drugdiscovery #podcast #AWS #AWSConversationsWithLeaders

Exscientia are the founding industrial partner of the AI for Drug Discovery Collaborative Training Partnership at the Digital Environment Research Institute (DERI), Queen Mary University of London, funded by BBSRC, and we are proud to celebrate a recent publication from a student in the first cohort of the programme. In this exciting paper, Dee et al. 2024 develop a new fusion AI model and achieve state-of-the-art performance in predicting drug mechanism of action from low-cost cell painting imaging datasets. Tools such as this can streamline the study of drug mechanism of action, helping us to design better drugs for patients.   https://lnkd.in/eNYnPimW #AI #AIDDCTP 

#MyCompany

We are delighted to announce that we have reached an agreement to acquire the full rights to our precision-designed oral CDK7 inhibitor, GTAEXS617 (‘617), from our partner, GT Apeiron.   ‘617 is currently in the monotherapy dose escalation part of the Phase 1/2 ELUCIDATE trial with data remaining on track to read out in the second half of this year.   This agreement maximises our upside potential for '617  David Hallett, Ph.D., our interim CEO and Chief Scientific Officer: “We are excited to have full ownership of this potentially transformative asset. CDK inhibitors are a major class of oncology drugs, and we believe our highly differentiated compound has the potential to greatly expand impact for patients and exemplifies our leadership in technology-driven drug design.”  Learn more: https://lnkd.in/eSmHTQeb   #CDK7 #drugdesign #AI #clinicaltrials #oncology